| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $418.8M | +5.6% |
| SG&A Expense | $136.6M | +29.5% |
| Operating Income | -$555.3M | -14.0% |
| Income Tax | $102K | +50.0% |
| Net Income | -$512.5M | -21.2% |
| EPS (Basic) | -$2.97 | -15.6% |
| EPS (Diluted) | -$2.97 | -15.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $205.3M | +17.4% |
| Short-term Investments | $662.6M | +0.8% |
| Accounts Receivable | $2.2M | +0.3% |
| Current Assets | $900.7M | +4.2% |
| Total Assets | $1.14B | -16.7% |
| Current Liabilities | $98.4M | -3.8% |
| Total Liabilities | $131.1M | -9.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$412.6M | -18.7% |
| Capital Expenditures | $9.5M | -40.3% |
| Investing Cash Flow | $255.3M | +387.6% |
| Financing Cash Flow | $189.2M | -60.9% |
| Free Cash Flow | -$422.1M | -16.1% |
| Stockholders' Equity |
| $1.01B |
| -17.6% |